After orthopaedic surgery, physicians and nurses strive to alleviate the short term pain typically by prescribing opioids. In order to assess and manage both pre and post-operative patient pain, UDT’s remain one of the best methods for determining patient response to opioid therapy in order to adjust treatment plans accordingly.
Opioids are the most effective medicines for moderate to severe pain, especially for managing short term pain after surgery, but patient individuality and patient misuse of opioids make UDT’s a necessity for physicians striving to protect patient health and provide the highest quality neuro-musculoskeletal services.
Beta BioScience’s state-of-the-art laboratories and exclusive methods provide physicians with accurate and timely results, affording them the ability to incorporate a testing policy that meets and exceeds the needs of both the patient and the practice.
Beta BioScience’s approach to UDT medication monitoring would include:
- Initial visit of a new patient
- Patients who receive a new prescription for a controlled substance
- Monthly testing recommendations for current patients receiving controlled substances at the doctor’s discretion
- Patients receiving medications post-operatively
- Patients receiving Schedule II drugs
- As part of a pre-operative workup
- Any new patient with existing prescriptions who request refills
- Monthly testing recommendations for patients with a history of illicit substance abuse at the doctor’s discretion
- Patients with a history of depression or other psychological disorders at the doctor’s discretion
- Anytime abuse of medication or controlled substances